ESMO and the Triple Meeting approach.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.

The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.

Genmab acquires the Dutch biotech for $8bn.

BNT329 enters the clinic, as do four other new ADCs.